Browse EX-10 agreements

MASTER SERVICES AGREEMENT

BY AND BETWEEN

PBT LAND AND MINERALS, INC.,

AS COMPANY,

AND

BLACKBEARD OPERATING, LLC,

AS SERVICE PROVIDER

TABLE OF CONTENTS

** **

		Page
Article I DEFINITIONS		1

…

Exhibit 10.51.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

EXPANSION CAPACITY AND ROFO AGREEMENT

THIS EXPANSION CAPACITY AND ROFO AGREEMENT (this “Agreement”), dated and effective as of the latest of the signatures below (the “Effective Date”), is entered into between Blockfusion USA, Inc., a Delaware corporation (“Blockfusion”) and CoreWeave, Inc., a Delaware corporation (“Tenant”).

RECITALS

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

LEASE

Between

NORTH EAST DATA, LLC

as Landlord

and

COREWEAVE, INC.

as Tenant

Dated

September 4, 2026

LEASE

This Lease (this “Lease”) is entered into as of the date (the “Effective Date”) of the later of the signatures below, by and between Landlord and Tenant:

RECITALS

A.  Landlord is the owner of the Land at 5380-5384 Frontier Avenue, Niagara Falls, New York 14304, as further described in Exhibit A-1 attached hereto. The Land is or will be improved with, among other things, the Building described in Exhibit A-1 attached hereto. The Land, the Building, and Landlord’s personal property thereon or therein may be referred to herein as the “Project.”

B. Tenant desires to lease the Premises (defined in Item 5 of the Basic Lease Information, below).

…

Exhibit 10.51.2

***  ***

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

September 4, 2026

CoreWeave, Inc.

290 W Mt. Pleasant Ave., Suite 4100

Livingston, NJ 07039

Attention: General Counsel

Email: [***]

** **

Re: Warrant Side Letter

Ladies and Gentlemen:

…

Execution Version

May 29, 2026

STRICTLY CONFIDENTIAL

Ketan Seth

Blue Acquisition Corp.

1601 Anita Lane

Newport Beach, CA 92660

Dear Ketan:

This letter (the “Agreement”), dated to be effective as of May 29, 2026 (the “Effective Date”), will confirm the basis upon which **Blue Acquisition Corp. **(“Company”) has engaged Northland Securities, Inc. (together with its affiliates, control persons, officers, directors, employees and agents, “Northland”), to act as capital markets advisor to the Company (the “Engagement”) to carry out the services described herein in connection with Company’s proposed business combination transaction (the “Transaction”) with Blockfusion USA, Inc. (the “Target”, and together with Company, the “Transaction Parties”). For purposes of this Agreement, the surviving public company in the proposed Transaction, Blockfusion Data Centers, Inc., a Delaware corporation, is referred to as “Pubco” or the “Combined Company” and all references to Company from and after the consummation, if any, of the proposed Transaction (the “BC Closing”)

…

Exhibit 10.51.3

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

COMPLETION GUARANTY

This COMPLETION GUARANTY (this “Guaranty”), dated as of September 4, 2026 (the “Effective Date”), is made by Blockfusion USA, Inc., a Delaware corporation (“Guarantor”), in favor of CoreWeave, Inc., a Delaware corporation (“Tenant”).

RECITALS:

**A. **WHEREAS, Tenant and North East Data, LLC, a Delaware limited liability company (“Landlord”), have entered into that certain Lease Agreement of even date herewith (as amended, restated, supplemented or otherwise modified from time to time, the “Lease Agreement”); and

**B.**WHEREAS, Guarantor will directly or indirectly benefit from the transactions contemplated by the Lease Agreement; and

**C. **WHEREAS, capitalized terms used and not defined herein have the meanings ascribed thereto in the Lease Agreement.

…

---

Exhibit 10.36

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10) (iv) of Regulation S-K. The omitted information is (i) not material and (ii) treated by the Registrant as private or confidential.

Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.

The Registrant undertakes to furnish a copy of all omitted information, schedules, and exhibits to the U.S. Securities and Exchange Commission upon its request.

Execution Version

Confidential

Research Collaboration and License Agreement

This Agreement is entered into with effect as of the Effective Date (as defined below)

by and between

F. Hoffmann-La Roche Ltd

with an office and place of business at [***] (“Roche Basel”)

and

Hoffmann-La Roche Inc.

with an office and place of business at [***] (“Roche US”; Roche Basel and Roche US together referred to as “Roche”) on the one hand

and

Remix Therapeutics, Inc.

with an office and place of business at [***] (“Remix”) on the other hand.

---

…

To:	Peter Ludlum
From:	Pulmatrix, Inc.
Date:	September 16, 2026
Subject:	Retention Bonus Opportunity

Pulmatrix, Inc. (the “Company”) views you as a valued member of our team, and we need you to help the Company meet the challenges ahead. To recognize your service to the Company, and to retain your ongoing and future services relationship with the Company, we are pleased to present you with a retention bonus opportunity, subject to the terms and conditions set forth below.

We appreciate your commitment to the Company. To accept this retention bonus opportunity, please sign, date and return this letter.

TERMS AND CONDITIONS

1.	Retention Bonus.

| | |

Palladium Capital Group, LLC

152 West 57TH Street, Floor 24

New York, NY 10019

Tel** (646) 485-7297**

JP@Palladiumcapital.Com

February 12, 2026

Peter Ludlum, Interim Chief Executive Officer

Pulmatrix, Inc.

945 Concord Street, Suite 1217

Framingham, MA 01701

	Re:	M&A Advisory Agreement

Dear Mr. Ludlum:

This letter agreement (this “Agreement”) sets forth the understanding and agreement between PALLADIUM CAPITAL GROUP, LLC, a Delaware limited liability company (“Palladium”), and PULMATRIX, INC., a Delaware corporation (the “Company”), with respect to the following:

…

**[***] **Certain identified information has been excluded from this exhibit because (i) it is not material and (ii) is the type that Pulmatrix treats as private or confidential.

Palladium Capital Group, LLC

Carnegie Hall Tower

152 West 57TH Street, Floor 24

New York, NY 10019

Tel** (646) 485-7297**

JP@Palladiumcapital.Com

** **

March 23, 2026

Kevin Slawin, M.D., Chief Executive Officer

Eos SENOLYTIX, Inc.

[***]

	Re:	Engagement Letter

Dear Dr. Slawin:

This letter agreement (this “Agreement”) sets forth the understanding and agreement between PALLADIUM CAPITAL GROUP, LLC, a Delaware limited liability company (“Palladium”), and EOS SENOLYTIX, INC., a Delaware corporation (the “Company”), with respect to the following:

…

EOS SENOLYTIX, INC.

2024 EQUITY INCENTIVE PLAN

1. Purpose; Eligibility.

1.1 General Purpose. The name of this plan is the EOS SENOLYTIX, INC. 2024 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable EOS SENOLYTIX, INC., a Delaware corporation (the “Company”), to attract and retain the types of Employees, Consultants and Directors who will contribute to the Company’s long range success; (b) provide incentives that align the interests of Employees, Consultants and Directors with those of the shareholders of the Company; and (c) promote the success of the Company’s business.

1.2 Eligible Award Recipients. The persons eligible to receive Awards are the Employees, Consultants and Directors of the Company and its Affiliates.

1.3 Available Awards. Awards that may be granted under the Plan include: (a) Incentive Stock Options, (b) Non-Qualified Stock Options, (c) Restricted Stock and (d) Restricted Stock Units.

2. Definitions.

…

**AVENZO THERAPEUTICS, INC. **

September 2, 2026

Elizabeth Mily

[***]

Dear Elizabeth:

We are very pleased to invite you to join the board of directors (the “Board”) of Avenzo Therapeutics, Inc. (the “Company”).

Following your appointment to the Board, which shall occur after the Company has obtained the requisite corporate approvals for such appointment, it will be recommended to the Board, or, following the closing of the Company’s pending merger transaction (the “Merger”), the board of directors of the post-merger public company, that you be granted an option to purchase 530,284 shares of the Company’s Class A common stock (as equitably adjusted to reflect the exchange ratio or any other capitalization adjustment applicable in connection with the Merger) (the “Common Stock”), at an exercise price per share equal to the then current fair market value of the Common Stock (the “Option”). The shares subject to the Option shall vest monthly over 36 months in equal monthly amounts following your appointment to the Board, subject to your continuing

…